PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTIONS, MARKED BY [***], HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. EXCLUSIVE SUBLICENSE AGREEMENTExclusive Sublicense Agreement • March 14th, 2007 • Bradley Pharmaceuticals Inc • Pharmaceutical preparations • Illinois
This AGREEMENT (“Agreement”), dated November 7, 2006 (the “Effective Date”), is made by and between BioSante Pharmaceuticals, Inc., 111 Barclay Boulevard, Lincolnshire, IL 60069 (“BPA”), and Bradley Pharmaceuticals, Inc., 383 Route 46 West, Fairfield, New Jersey 07004-2402 (“Company”).
FIFTH AMENDMENT TO DISTRIBUTION AGREEMENTDistribution Agreement • March 14th, 2007 • Bradley Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Fifth Amendment to Distribution Agreement (this “Amendment”), dated as of June 22, 2006, is made by Par Pharmaceutical, Inc., a Delaware corporation (successor by merger to Par Pharmaceutical, Inc., a New Jersey corporation) (“Par”), and Bradley Pharmaceuticals, Inc., a Delaware corporation (“Bradley”).
FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENTCredit Agreement • March 14th, 2007 • Bradley Pharmaceuticals Inc • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of March 9, 2007 (this “Amendment”), is by and among BRADLEY PHARMACEUTICALS, INC., a Delaware corporation (the “Borrower”), those Domestic Subsidiaries of the Borrower identified as “Guarantors” on the signature pages hereto and such other Domestic Subsidiaries of the Borrower as may from time to time become a party hereto (collectively, the “Guarantors”), and WACHOVIA BANK, NATIONAL ASSOCIATION, a national banking association, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”).
FOURTH AMENDMENT TO DISTRIBUTION AGREEMENTDistribution Agreement • March 14th, 2007 • Bradley Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Fourth Amendment to Distribution Agreement (this “Amendment”), dated as of February 1, 2005, is by and between Par Pharmaceutical, Inc., a Delaware corporation (successor by merger to Par Pharmaceutical, Inc., a New Jersey corporation) (“Par”), and Bradley Pharmaceuticals, Inc., a Delaware corporation (“Bradley”).
